GUFICBIO.NSNSE
Gufic Biosciences Limited
₹332.15
ListedOct 19, 2004
SectorHealthcare
IndustryDrug Manufacturers — Specialty & Generic
CountryIndia
Employees1484
State-| CityMumbai| AddressS.M. House| Phone91 22 6726 1000
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.

Key Indicators

Key financial and dividend metrics for this stock.

?
P/E Ratio
66.8
?
Div. Rate
₹0.10
?
Div. Yield
0.03%
?
Payout Ratio
2.01%
?
Max Consec. Div. Years
18 years
?
Longest Consec. Div.
18 years
?
Div. Coverage
95%
?
Div. Stability Rate
0.00
?
Div. Growth Rate
0.00%
?
Score
79

Dividend History

Historical dividend payments by ex-dividend date.

Sep 22, 2025
₹ 0.1000
Sep 17, 2024
₹ 0.1000
Sep 21, 2023
₹ 0.1000
Aug 24, 2022
₹ 0.1000
Sep 9, 2021
₹ 0.1000
Nov 3, 2020
₹ 0.0500
Sep 20, 2019
₹ 0.0500
Sep 19, 2018
₹ 0.0500
Aug 28, 2017
₹ 0.0500
Sep 19, 2016
₹ 0.0500
Sep 22, 2015
₹ 0.0500
Sep 18, 2014
₹ 0.0500
Sep 19, 2013
₹ 0.0500
Sep 2, 2013
₹ 0.0500
Aug 16, 2012
₹ 0.0500
Sep 16, 2011
₹ 0.0500
Sep 20, 2010
₹ 0.0500
Sep 17, 2009
₹ 0.0500
Dec 11, 2008
₹ 0.0500
Mar 19, 2008
₹ 0.0500
Sep 20, 2006
₹ 0.1600
Sep 22, 2005
₹ 0.2200

Peer Companies

Other stocks in the same sector.

The app download will be available in the next version. Stay tuned!